Study of Potential Drug–Drug Interactions in Pediatric Prescriptions: A Hospital-Based Analysis

Drug–drug interactions (DDIs) represent a significant clinical challenge, especially in pediatric populations, where multiple drug prescriptions are common. DDIs can alter drug efficacy or toxicity, leading to adverse outcomes, including hospitalization and increased mortality rates. This observational study aimed to assess potential DDIs in pediatric prescriptions at Sadguru Clinic, Zarekati Taluka, Sangamner District, Ahmednagar, using a drug interaction checker. The study focused on pediatric patients prescribed more than two medications, including Advent 228.5 (Amoxicillin and Clavulanic Acid), Maxtra (Chlorpheniramine Maleate and Phenylephrine), Fevfast (Mefenamic Acid and Paracetamol), and Mucolite (Ambroxol). A total of 16 potential interactions were identified, categorized as minor, moderate, or major. Interactions between Amoxicillin and Chlorpheniramine were found to be minor, while combinations of Chlorpheniramine with Phenylephrine, Mefenamic Acid, and Paracetamol were categorized as moderate. The study emphasizes the importance of carefully monitoring drug combinations, particularly in pediatric patients, to minimize potential risks. The findings highlight the need for systematic use of drug interaction software in clinical settings to ensure safer drug prescribing practices. Awareness of potential DDIs and their management could significantly improve patient safety and therapeutic outcomes, reducing medication-related complications in pediatric care.